![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Synabridge Corporation Yale University Columbia University University of Alabama at Birmingham University of Tennessee |
Information provided by: | Synabridge Corporation |
ClinicalTrials.gov Identifier: | NCT00578110 |
To introduce a rapid and objective electrophysiological technique that can assess visual function in the magnocellular pathway, which is thought to be affected in early-stage glaucoma.
Condition | Intervention |
Glaucoma |
Device: Glaucoma Diagnosis, Name: Neucodia |
Genetics Home Reference related topics: | early-onset glaucoma |
MedlinePlus related topics: | Glaucoma |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | SBIR II Instrument for Glaucoma Early Detection and Monitoring |
Estimated Enrollment: | 180 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2008 |
Arms | Assigned Interventions |
1: Experimental
Glaucoma Patients
|
Device: Glaucoma Diagnosis, Name: Neucodia
Sensitivity and Specificity
|
2: Experimental
Glaucoma suspects
|
Device: Glaucoma Diagnosis, Name: Neucodia
Sensitivity and Specificity
|
3: Active Comparator
Controls
|
Device: Glaucoma Diagnosis, Name: Neucodia
Sensitivity and Specificity
|
Ages Eligible for Study: | 40 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: George Hu, Ph.D. | (908) 725-5213 | georgehu@synabridge.com |
Contact: Vance Zemon, Ph.D. | (845) 627-0320 | vepman@aol.com |
United States, Connecticut | |||||
Yale Eye Center | Not yet recruiting | ||||
New Haven, Connecticut, United States, 06510 | |||||
Contact: Ann Leone 203-785-6150 ann.leone@yale.edu | |||||
Principal Investigator: James C Tsai, M.D. MBA | |||||
United States, New Jersey | |||||
Synabridge Corp. | Active, not recruiting | ||||
Raritan, New Jersey, United States, 08869 |
Synabridge Corporation |
Yale University |
Columbia University |
University of Alabama at Birmingham |
University of Tennessee |
Principal Investigator: | George Hu, Ph.D. | Synabridge Corp. |
Principal Investigator: | James Tsai, M.D. | Yale University |
Study Director: | Max Forbes, M.D. | Columbia University |
Study Director: | Vivienne Greenstein, Ph.D. | Columbia University |
Principal Investigator: | Eugenue Hartmann, Ph.D. | University of Alabama at Birmingham |
Principal Investigator: | Peter Netland, M.D. Ph.D. | University of Tennessee |
Study Director: | Leo Pau Semes, O.D. | University of Alabama at Birmingham |
Study Director: | Vance M Zemon, Ph.D. | Yeshiva University |
Responsible Party: | Synabridge Corp. ( George Hu, President ) |
Study ID Numbers: | OPTH_DEV_GLAU_02, 1R43EY015015-01, 1R43EY015015-02 |
First Received: | December 11, 2007 |
Last Updated: | December 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00578110 |
Health Authority: | United States: Institutional Review Board |
|
|
![]() |